Editing streptomycete genomes in the CRISPR/Cas9 age by Alberti, Fabrizio & Corre, Christophe
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Published Version 
The version presented in WRAP is the published version (Version of Record). 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/114645                            
 
How to cite: 
The repository item page linked to above, will contain details on accessing citation guidance 
from the publisher. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 3.0 International 
license (CC BY 3.0) and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/3.0/. 
 
 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
Natural Product
Reports
HIGHLIGHT
Pu
bl
ish
ed
 o
n 
25
 Ja
nu
ar
y 
20
19
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f W
ar
w
ic
k 
on
 1
/2
6/
20
19
 1
1:
37
:4
7 
A
M
. 
View Article Online
View JournalEditing streptomSchool of Life Sciences, Department of Chem
Road, Coventry CV4 7AL, UK. E-mail: C.Cor
Cite this: DOI: 10.1039/c8np00081f
Received 24th September 2018
DOI: 10.1039/c8np00081f
rsc.li/npr
This journal is © The Royal Society ofycete genomes in the
CRISPR/Cas9 age
Fabrizio Alberti and Christophe Corre *
Covering: up to December 2018
This article aims to highlight advantages, drawbacks and issues that users should consider when
implementing the use of CRISPR/Cas9-tools for genome editing in streptomycetes, the most proliﬁc
source of antimicrobial natural products to date. Here, we examine four toolkits that have so far been
made available for streptomycete in vivo-engineering and one for in vitro-editing, and review how they
have been applied over the last three years. Our critical evaluation of these toolkits intends to support
potential users in determining what they could achieve, what they should consider and what system they
should select/optimise for their application.1 Introduction
Streptomycetes are Gram-positive lamentous bacteria known
for their ability to produce a wide variety of bioactive metabo-
lites (Fig. 1) and recognised as the primary producers of the
antibiotics currently used in human and veterinary medicine or
undergoing clinical development.1 The cyclic lipopeptide dap-
tomycin (1) is one the most prominent examples of antibiotics
made by streptomycetes and recently exploited in the clinic.
This natural product is used to treat complicated skin and skin
structure infections, as well as bacteremia and endocarditis
caused by Staphylococcus aureus.2 Streptomycetes are also
acknowledged producers of useful bioactive molecules that nd
application in various other elds, such as the anthelmintic
agents avermectins (2)3 and the herbicide bialaphos (3).4 Whole
genome sequencing of streptomycetes has uncovered a plethora
of cryptic biosynthetic gene clusters (BGCs), revealing that only
a small fraction of the natural products encoded at the DNA
level has been exploited.
In this context, genetic engineering of streptomycetes is
recognised as a valuable approach to discover new bioactive
compounds.5 Traditionally, editing of their genomes has been
achieved using validated but oen time-consuming protocols,
such as RecA-mediated double-crossover homologous recom-
bination using bespoke suicide plasmids or cosmids modied
by l-Red-mediated homologous recombination.6,7 More
recently, targeted genome editing has been revolutionised by
the advent of clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated (Cas) systems, which form
the basis for the CRISPR/Cas9-based genome editingistry, University of Warwick, Gibbet Hill
re@warwick.ac.uk
Chemistry 2019technology.8 For a comprehensive overview of the mechanism
behind CRISPR/Cas9-based genome editing we invite the reader
to refer to the review by Tong et al.9
Following the advent of CRISPR/Cas systems, toolkits for
editing streptomycete genomes have quickly been estab-
lished,10–13 enabling researchers working on these microorgan-
isms to overcome the issues associated with classical methods
of gene disruption. This article will highlight the advantages,
drawbacks and issues related to streptomycete genome editing
through CRISPR/Cas systems, looking at all the instances in
which the various CRISPR/Cas9-based toolkits have been used
in the last three years for the purpose of natural product iden-
tication and characterisation.2 Pre-CRISPR/Cas9 strategies to
manipulate streptomycete genomes
Streptomycete genomes can be engineered by exploiting
homologous recombination either via single or double cross-
over events.6 Insertion of a selectable marker using single
crossover can be suﬃcient for the purpose of gene disruption.
However, integration of the entire plasmid can result in polar
eﬀects, disrupting the expression of downstream genes. Other
issues include reversion to the wild-type genotype in the
absence of suitable selective pressure and the limited number
of selectable markers (apramycin, hygromycin and kanamycin
being the most reliable) eﬀective in streptomycetes, which also
prevents multiple events of genome editing using this
approach. Double crossovers lead to more stable and “cleaner”
mutations but require multiple steps, making the process more
laborious (Fig. 2). First the DNA construct has to be integrated at
the target locus (through single crossover), which is typically
selected for using a selectable marker that is placed between theNat. Prod. Rep.
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View Article Onlinetwo homologous recombination arms; the second integration
event (resulting in a double crossover) is then selected for via
screening for loss of another selectable marker, which is instead
located in the backbone vector; lastly, replica plating is used to
discern between the mutants that derive from double crossover
(and contain the desired genotype) and the strains that have
instead reverted to the wild-type genotype.6 The intrinsic
frequency of double crossover in streptomycetes is strain-
dependent and can be extremely low.
A signicant improvement for streptomycete genome engi-
neering was achieved in 2003 with the introduction of a Red/ET-
based recombineering approach. Cosmid clones could be
rapidly edited using l-Red-mediated homologous recombina-
tion in E. coli and introduced into streptomycetes for genome
engineering.7 Generating and screening for the desired double
crossover events in streptomycete DNA remained a relatively
lengthy process (Fig. 2). However, a couple of strategies have
been developed to improve the process of selecting double
crossovers. For instance, introducing a unique 18 bp recogni-
tion site for the meganuclease I-SceI in the backbone of the DNA
construct makes the integrated DNA (via single crossover)
susceptible to double-stranded breaks (DSBs) when I-SceI is
expressed in the strain of interest.14 Repair of the DNA break by
homologous recombination provides a potent positive selection
for double crossover mutants.14 It is important to note the
potential toxicity of I-SceI and the possible presence of the 18 bp
recognition site in the genome of the strain under study.
Another improvement of the selection process came with the
introduction of the gusA blue-white screening for single and
double crossover.14 In this system, ex-conjugants are overlaid
with X-Gluc (5-bromo-4-chloro-3-indolyl-b-D-glucuronide),
which gives rise to a blue product when the b-glucuronidase
gusA gene is still present in the plasmid backbone either in
a free plasmid or in a single crossover conguration. When theFabrizio Alberti completed his
Ph.D. in 2015 at the University
of Bristol, where he studied the
biosynthesis of fungal natural
products under the supervision
of Prof. Gary Foster and Dr Andy
Bailey. He then joined Dr
Christophe Corre's group at the
University of Warwick as a post-
doctoral research fellow to work
on natural product discovery
from streptomycetes and the
development of whole-cell bio-
catalysts. In 2018 he became a Leverhulme Trust Early Career
Fellow at the same institution, where he currently focuses on the
elucidation of biosynthetic pathways of fungal meroterpenoid
natural products.
Nat. Prod. Rep.double crossover has happened, and the plasmid backbone has
been lost, the colonies with the desired mutation will instead
appear white. This visual screening reduces the overall time of
a Red/ET-based recombineering experiment but still compels to
passage ex-conjugants 5 to 10 times in liquid medium to enrich
for cells with double crossovers.14
3 Strategies for in vivo CRISPR/Cas9-
based streptomycete genome
engineering
When Charpentier and colleagues described the use of CRISPR/
Cas9 to introduce DSBs in target DNA in Streptococcus pyogenes,8
they prompted scientists around the globe to adapt this system
for the use in other hosts. Since then, protocols for CRISPR/
Cas9-mediated genome editing have been developed for
organisms across all domains of life, such as for the unicellular
model organisms Escherichia coli and Saccharomyces cerevisiae,
the archeon Methanosarcina acetivorans, the model plants Ara-
bidopsis thaliana and Nicotiana benthamiana, zebrash, mouse
and human cell lines.15 In brief, CRISPR/Cas9-based genome
engineering relies on the ability of the endonuclease Cas9 to
cleave a target double-stranded DNA (dsDNA). Cas9 function-
ality depends upon the interaction with a dual-RNA structure
that comprises of a CRISPR-RNA (crRNA) and a trans-activating
crRNA (tracrRNA). These two can also be fused together, giving
rise to a synthetic guide-RNA (sgRNA). The specic target site for
the DSB is determined through a 20 bp protospacer seed
sequence in the crRNA which must be followed in the target
DNA by a protospacer adjacent motif (PAM, NGG for S. pyogenes,
where N can be any nucleotide). The DSB in the target dsDNA
occurs three bp upstream of the PAM sequence and can be
repaired either through the error-prone non-homologous end
joining (NHEJ) pathway or through the more eﬃcient andChristophe Corre is an Associate
Professor in Synthetic Biology;
jointly appointed between the
School of Life Sciences and the
Department of Chemistry at the
University of Warwick, UK. His
research group is particularly
interested in streptomycete
transcriptional regulators, bio-
catalysts and natural products.
Christophe received his educa-
tion in Biochemistry and Molec-
ular Biology at the University of
Nice in France. He then carried out work on antibiotic biosynthesis
for which he was awarded a PhD in Chemistry at the University of
Exeter, UK. He then moved to Warwick in 2004 to work as a post-
doctoral research fellow in Prof. Greg Challis group. In 2010,
Christophe was awarded a Royal Society University Research
Fellowship to unlock the production of novel microbial antibiotics
and to start his independent research group at Warwick.
This journal is © The Royal Society of Chemistry 2019
Fig. 1 Chemical structures of natural products from streptomycetes and other bacteria mentioned in this article.
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View Article Onlineaccurate homology-directed repair (HDR). When HDR is
chosen, precise genome editing can be achieved through
introduction of a user-designed editing template or homolo-
gous recombination (HR) arms.This journal is © The Royal Society of Chemistry 2019Given the importance of streptomycetes in natural product
discovery and the lack of a quick, eﬃcient and programmable
method for their genome engineering, diﬀerent CRISPR/Cas9-
based toolkits for the genome editing of these bacteria haveNat. Prod. Rep.
Fig. 2 Overview of the diﬀerent strategies available for streptomycete genome engineering. aClearance of the plasmid can take an additional 3–
4 days through subculture at increased temperature (37–39 C) when pSG5-based plasmids are used.10–12
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View Article Onlinebeen developed. Four diﬀerent CRISPR/Cas9-based systems for
in vivo editing of streptomycetes were made available between
November 2014 and August 2015 and are quickly being imple-
mented as a routine engineering strategy by many groups
around the world to study natural product biosynthesis and
regulation.3.1 Key considerations
As with previously described genetic engineering approaches
(Section 2), a pre-requisite of using the CRISPR-Cas9 system
currently available is the genetic tractability of the streptomy-
cete species under study. However, when investigating or
exploiting natural product BGCs, one can clone and introduce
the entire pathway into a genetically tractable heterologous host
where specic toolkits have been validated (Table 1). Cloning of
the BGC can be performed either via the classic generation of
cosmid libraries, or through other more recently-developed
techniques, such as transformation-associated recombination
(TAR) cloning.16 For instance, using a combination of TAR
cloning to capture a cryptic and silent BGC and pCRISPomyces-
2 (Section 3.2) to inactivate one of the cluster-specic tran-
scriptional repressors, our group have recently discovered and
characterised the biosynthesis of the novel L-proline derivative
scleric acid (4).17
Other potential and critical issues, more specic to CRISPR/
Cas9 systems are: (i) toxicity of Cas9 in the specic strain used,Nat. Prod. Rep.as reported by Rohr and colleagues in Streptomyces sp. KY 40-1
(ref. 18) and (ii) poor expression of the cas9 gene or that of
sgRNA(s).
Another concern to take into account when using CRISPR/
Cas9 systems is that all four streptomycete toolkits currently
available rely on the same selectable marker, apramycin. Since
some streptomycete strains are known to be naturally resistant
to apramycin, the lack of an alternative selectable marker is
limiting the potential of these toolkits.
A similar consideration can be made on the ease of
assembly of a construct for the specic genome engineering,
which can aﬀect the timeframe of the experiment. All four kits
for in vivo streptomycete genome engineering require to insert
both a 20 bp sgRNA and longer HR arms (normally between 1
and 2 kb). Plasmids developed by Zhao and colleagues10
combine a rst eﬃcient Golden Gate assembly19 step for the
insertion of the sgRNA and a second Gibson assembly19 step
for the insertion of the HR arms. Plasmid pKCcas9dO from the
Hu, Lu and colleagues11 is assembled by the authors through
a single Gibson assembly19 step between the backbone and
a linear DNA string generated through overlapping extension
PCR to include both sgRNA and HR arms. Lastly, toolkits
developed by Weber, Lee and colleagues12 and Sun and
colleagues13 require a rst traditional cloning step for inser-
tion of the sgRNA and a second Gibson assembly19 step for the
insertion of the HR arms.This journal is © The Royal Society of Chemistry 2019
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View Article Online3.2 pCRISPomyces plasmids from Zhao and colleagues10
The rst CRISPR/Cas9-based toolkit for streptomycetes that
became widely available was developed in the Zhao lab, at the
University of Illinois, Urbana (US). Two plasmids, named
pCRISPomyces-1 and pCRISPomyces-2, were developed (Fig. 3).
The rst one contains separate crRNA and tracrRNA cassettes,
whereas the second one includes an sgRNA cassette in which
the tracrRNA and the crRNA have been fused to give a chimeric
molecule. The sgRNA is known to have at least the same editing
eﬃciency as if using separate tracrRNA and crRNA.8 These two
plasmids include elements for maintenance and selection in E.
coli and streptomycetes, such as the temperature sensitive
replication (rep) region from pSG5,20 which allows for clearance
of the plasmid once the genome editing has been accomplished
(see Table 1 for a list of the main features of these and the otherFig. 3 Maps of plasmids for in vivoCRISPR/Cas9-based engineering of st
apramycin resistance; HR arms: homologous recombination arms for
codA(sm): cytosine deaminase gene for the use of 5-ﬂuorocytosine as a
in green, as opposed to all other constitutive promoters represented in
Nat. Prod. Rep.plasmids reviewed in this article). The streptomycetes codon-
optimised cas9 gene included in these two plasmids is placed
under control of the strong constitutive promoter rpsLp (CF,
from Cellulomonas avigena).21 Similarly, the sgRNA cassette in
pCRISPomyces-2 (as well as the crRNA of pCRISPomyces-1 that
has to be inserted by the user with the specic protospacer of
choice) is placed under control of the gapdhp (EL, from Egger-
thella lenta) strong promoter.21 Both promoters have been
characterised as being able to drive strong expression in the
heterologous host Streptomyces lividans, showing more than
a 10-fold higher activity compared to ermE*p, which is
a commonly used promoter for heterologous expression in
streptomycetes.22 As well as in S. lividans, rpsLp (CF) and gapdhp
(EL) have also shown the ability to drive heterologous gene
expression at high levels in additional commonly usedreptomycetes.10–13 sgRNA: synthetic guide-RNA; aprR: aac(3)IV gene for
homology-directed repair; thioR: gene for thiostrepton resistance;
counter-selectable marker; tipAp is an inducible promoter represented
black.
This journal is © The Royal Society of Chemistry 2019
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View Article Onlinestreptomycete hosts, such as Streptomyces albus J1074, Strepto-
myces venezuelae ISP5230, Streptomyces coelicolor M1146 and
Streptomyces avermitilis SUKA16.22 Indeed, Zhao and colleagues
tested the eﬃcacy of their two CRISPR/Cas9 plasmids in
diﬀerent hosts: pCRISPomyces-1 was used to generate short
deletions in S. lividans, whereas pCRISPomyces-2 was success-
fully employed to produce short and large deletions in S. livid-
ans, S. albus and S. viridochromogenes.10 The eﬃciency of
pCRISPomyces-1 was considerably lower than that of
pCRISPomyces-2. The plasmid with separate tracrRNA and
crRNA cassettes showed editing eﬃciency of around 20–25%, as
opposed to an eﬃciency of 67 to 100% for the plasmid with
sgRNA. The authors hypothesise that the pre-crRNA may not be
processed very eﬃciently by the native RNase enzymes within
streptomycetes, leading to a reduced editing eﬃciency for
pCRISPomyces-1. As well as to generate individual short and
large deletions from 20 bp to 31 kb with either one or two
protospacer sequences (with two protospacers used for large
deletions), worth noting is that pCRISPomyces-2 was also
employed to successfully introduce simultaneous short dele-
tions in two diﬀerent loci, showing the potential to be used for
multiplex genome editing.10 The authors reported that in one
instance editing with pCRISPomyces-2 in S. albus aimed at
deleting a 13 kb region resulted in production of a chimeric
strain where a mixture of wild-type and mutated cells were
present. Despite the relatively small size of streptomycete
genomes and the consequent low probability of occurrence, the
authors did not screen the mutants generated with their
CRISPR/Cas9 plasmids for oﬀ-target eﬀects of the activity of
Cas9, which have been reported to be one of the main draw-
backs of CRISPR/Cas9-based genome editing.23 Nevertheless,
Zhao and collaborators reported to have chosen protospacers in
which the last 12 bp plus protospacer adjacent motif (PAM)
sequence (in total 15 bp) were unique in the genome of the
target species, which is known to minimise oﬀ-target eﬀects.10
Since its release, pCRISPomyces-2 has been successfully
employed by other groups to edit the genome of various strep-
tomycetes, demonstrating its potential for the engineering of
both established hosts and other less commonly used
strains.17,24–31 For instance, Hutchings and collaborators used it
to generate both one-gene and whole-cluster deletions in
Streptomyces formicae to conrm the identity of the antibiotic
formicamycin (5) BGC and study the activity of the cluster-
included halogenase ForV.25 The plasmid pCRISPomyces-2
was also employed by Zhang and colleagues to generate point-
mutations and small deletions to increase oxytetracycline (6)
production in Streptomyces rimosus,26 as well as by Metsa¨-Ketela
and colleagues to investigate glycosylation of the nucleoside
antibiotic showdomycin (7) in Streptomyces showdoensis.27 As
well as for generating deletions,10 the same authors who
developed pCRISPomyces-2 later used this plasmid for the
precise insertion of single or bidirectional heterologous
promoters to activate silent BGC in S. albus, S. lividans, Strep-
tomyces roseosporus, S. venezuelae and S. viridochromogenes.28
Other than streptomycetes, pCRISPomyces-2 has also success-
fully been employed to edit the genome of other bacteria, such
as Actinoplanes sp. SE50/110 (ref. 29) and the Gram-negativeThis journal is © The Royal Society of Chemistry 2019cyanobacterium Synechococcus elongatus,30 opening the way for
the use of this CRISPR/Cas9 plasmid in a wider variety of
organisms. Despite several examples of successful engineering of
streptomycetes and other bacteria with pCRISPomyces-2,
however, the promoters used to drive expression of the cas9
gene and that of the sgRNAmay not currently be optimal in every
streptomycete strains, let alone with other unrelated species, but
could be optimised. Interestingly, Schmid and colleagues cus-
tomised pCRISPomyces-2 for expression in Paenibacillus poly-
myxa by replacing the rpsLp (CF) promoter that guides expression
of the cas9 gene, for a promoter that was previously characterised
to drive strong expression in Paenibacillus, while keeping the
gapdhp (EL) promoter for expression of the sgRNA.313.3 pKCcas9dO plasmid from Hu, Lu and colleagues11
The second CRISPR/Cas9 toolkit that became available for
streptomycete genome editing was developed by the Hu and Lu
laboratories at the Shanghai Institutes for Biological Sciences
and Pharmaceutical Industry, China. This plasmid features, as
seen in pCRISPomyces-2, a chimeric sgRNA cassette, placed
here under control of the synthetic constitutive promoter
j23119, which has been designed and tested for expression in E.
coli.32 The cas9 gene present in this plasmid was codon-
optimised for the codon usage of Streptomyces coelicolor and
placed under control of the inducible promoter tipAp.33 In the
rst place, pKCcas9dO (Fig. 3) was tested as a tool to engineer
the genome of the model organism S. coelicolorM145, resulting
in editing eﬃciency of 29–100% for single and multiplex gene
deletions between 745 and 1053 bp, as well as of 38–100% for
single and multiplex antibiotic BGC deletions of size ranging
between 21.3 and 82.8 kb. Interestingly, the authors reported
a higher deletion eﬃciency when editing the actinorhodin (8)
BGC (100%) than when attempting to edit the undecylprodi-
giosin (9) BGC (29–71%). A similar problem was observed by the
authors when attempting a simultaneous double deletion of
BGCs for 8 and 9, which was resolved by using an alternative
sgRNA to target cleavage within the BGC for 9. Moreover,
a mixed phenotype was reported by the authors when
attempting single-gene deletion in the BGC for 9, suggesting an
ineﬃcient cleavage for the sgRNA. As the cleavage eﬃciency did
not seem to be related to the size of the desired deletion, it can
be speculated that other factors may be the cause for this. For
instance, potential secondary structures formed by the sgRNA
could in turn aﬀect its interaction with Cas9, decreasing the
editing eﬃciency.13 As well as to generate deletions, the authors
successfully used their CRISPR/Cas9 plasmid to introduce
point-mutations into the rpsL gene of S. coelicolor, with the aim
of confering resistance to streptomycin (10), similarly to the
work from Zhang and colleagues using pCRISPomyces-2 to
increase production of 6 in S. rimosus.26 The plasmid
pKCcas9dO was also tested in Streptomyces pristinaespiralis, for
which the authors reported a 25 kb BGC deletion with 94%
eﬃciency, suggesting that their toolkit could be used also in
non-model streptomycete species. Indeed, the same plasmid
has been used by other research groups to edit streptomycete
genomes.34–38 For instance, the same authors later used thisNat. Prod. Rep.
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View Article Onlinetoolkit on S. pristinaespiralis to study the regulation of the
biosynthesis of the antibiotic pristinamycin I through genera-
tion of point-mutations,34 as well as to increase its production
titres through deletion of the cluster-specic transcriptional
repressors.35 In two other instances pKCcas9dO has been used
to edit the genome of S. coelicolor: (i) to study the regulation
mechanism of the two-component system AfsQ1/Q2 in coeli-
mycin P2 biosynthesis,36 and (ii) to conrm the involvement of
the global transcriptional regulator GlnR in antibiotic biosyn-
thesis regulation.37 In addition to the two species in which
pKCcas9dO was originally tested, Zhao and colleagues used this
plasmid on Streptomyces cinnamonensis to generate a gene-
deletion that proved the positive regulatory eﬀect of DasR in
biosynthesis of the polyether antibiotic monensin.383.4 pCRISPR-Cas9 and pCRISPR-dCas9 plasmids from
Weber, Lee and colleagues12
The third CRISPR-Cas9 toolkit to become available for use in
streptomycetes was developed by the groups of Weber and Lee
at DTU, Denmark. Similarly to pKCcas9dO, pCRISPR-Cas9
(Fig. 3) also allows for an inducible expression of the cas9
gene (codon-optimised for the codon usage of S. coelicolor),
through the promoter tipAp. However, as highlighted by the
authors, this inducible system can only work in streptomycete
strains that, like S. coelicolor, have a copy of the thiostrepton
responsive activator TipA in their genome.39 The promoter that
drives expression of the sgRNA in pCRISPR-Cas9 is instead
ermE*p. This has been used for many years in heterologous
expression of streptomycete genes, despite there being other
promoters with increased strength.22 Weber, Lee and colleagues
tested their pCRISPR-Cas9 plasmid on the model organism S.
coelicolor A3(2), targeting six diﬀerent positions for each of the
two genes actIORF1 and actVB involved in the biosynthetic
pathway for 8. Interestingly, the authors showed that the DSBs
generated through their toolkit can be repaired, with diﬀerent
eﬃciencies, exploiting either the error-prone NHEJ pathway or
through HDR. In the rst case, no templates for homology-
directed repair are provided with the plasmid but only the 20
bp protospacer within the sgRNA. This led to an editing eﬃ-
ciency that ranged between 3 and 54%, where the NHEJ pathway
repaired the DSB giving insertions and deletions of various sizes
but all at the desired target site. Introduction of a heterologous
DNA Ligase D gene (LigD) resulted in a more eﬃcient NHEJ
pathway, which increased the positive outcome of CRISPR/
Cas9-based deletion to 37–77%. In these strains, the extension
of insertion or deletions by the target site decreased consider-
ably in size compared to those strains generated through an
incomplete NHEJ pathway. Lastly, the authors designed
pCRISPR-Cas9 plasmids with 2.2 kb homologous recombina-
tion templates and used them to target the same two genes of
the 8 pathway, resulting in correct deletion in almost 100% of
the cases. The authors conrmed in all cases through whole-
genome sequencing that no oﬀ-target eﬀects had occurred
when performing CRISPR/Cas9 engineering. As well as to
generate genomic deletions, Weber, Lee and colleagues also
used their toolkit to perform CRISPR interference (CRISPRi),Nat. Prod. Rep.similarly to what was shown previously in E. coli by Lim and
colleagues.40 In order to do so, the authors inactivated both
nuclease domains (RuvC1 and HNH) of the cas9 gene targeting
a single amino acid position in each region, resulting in
a catalytically inactive (or dead, dCas9) enzyme variant that lost
its endonuclease activity. The dCas9 sterically blocked gene
expression, leading to loss or considerably reduced production
of 8, only when the sgRNA targeted the promoter region of the
genes under study or the non-template strand of their coding
sequence.
The CRISPR-Cas9 systems developed by Weber, Lee and
colleagues were successfully employed to knockout and
knockdown genes in the industrially-relevant species Coryne-
bacterium glutamicum, targeting genes involved in production of
g-aminobutyric acid (11).41 The plasmid pCRISPR-Cas9 was also
employed by Liang and collaborators to conrm the identity of
the BGC for the polyene macrolactam sceliphrolactam (12) from
a streptomycete strain isolated from a mangrove sediment.42
Interestingly, the authors reported that only one of the ve
protospacers used to attempt deletion of the target polyketide
synthase (PKS) module led to successful gene knockout, with
the other four protospacers giving no genome editing in strain
Streptomyces SD-85.42 Plasmid pCRISPR-Cas9 was also success-
fully employed in another non-streptomycete species by Cohen
and Townsend.43 Here the authors used this plasmid to delete
two cytochrome P450 genes and eight potential PKS genes from
the genome of Micromonospora chersina, in the search for the
PKS that would be responsible for production of the anthra-
quinone portion of the antitumor antibiotic dynemicin A (13).
Deletion of a ninth putative PKS was not successful but this was
explained by the potentially essential role of this gene rather
than by the ineﬃcacy of pCRISPR-Cas9.3.5 pWHU2650 and derived plasmids from Sun and
colleagues13
The most recent CRISPR-Cas9 toolkit for streptomycetes to
become available was developed by Sun and collaborators, from
the University of Wuhan, China. This includes the progenitor
plasmid pWHU2650, which similarly to pCRISPR-Cas9, features
a constitutive ermE*p promoter to control expression of the
streptomycete codon-optimised cas9 gene. The sgRNA is instead
under control of the aac(3)IVp promoter from the aminoglyco-
side 3-N-acetyltransferase type IV gene,44 which is commonly
used as a selectable marker in E. coli/Streptomyces shuttle
vectors to confer resistance to apramycin and is indeed the
selectable marker found in all four CRISPR/Cas9-based toolkits
for streptomycete genome editing reviewed here. As seen for
pKCcas9dO and pCRISPR/Cas9, Sun and co-workers tested their
pWHU2650 plasmid on the model species S. coelicolor M145,
targeting genes involved in the biosynthesis of 8. The authors
reported that introduction of their plasmid with a sgRNA, but
without any template for homology-directed repair, into S.
coelicolor resulted in generation of only seven ex-conjugants,
which showed no changes at the target site. Adding HR arms
of approximately 2 kb each led instead to the precise deletion of
the actI-ORF2 gene (939 bp). The editing eﬃciency rangedThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinebetween 93 and 99%, depending on which of the two diﬀerent
sgRNA templates (of 48 and 95 bp respectively) were used as
a scaﬀold to clone the 20 bp protospacer. Interestingly, the
authors also carried out a control experiment where they
introduced the plasmid with cas9 gene and the homologous
arms, without sgRNA, but this resulted in an editing eﬃciency
of only 4%, supporting the essential role of the Cas9-generated
DSB to enhance homology-directed repair. In order to accelerate
the screening process and carry out more rounds of consecutive
genome editing, Sun and co-workers introduced the cytosine
deaminase gene codA(sm) in their CRISPR/Cas9 plasmid,
generating the backbone plasmid pWHU2653 (Fig. 3) as well as
plasmid pWHU2659 with sgRNA and HR arms to target the actI-
ORF2 gene. When ex-conjugants are grown on plates that
contain 5-uorocytosine (5FC), CodA converts it into 5-uoro-
uracil (5FU), functioning as a counter-selectable marker.45 This
allows to produce a marker-free progeny that can be further
subjected to another round of CRISPR/Cas9-based engineering.
The presence of such counter-selectable marker for plasmid
clearance is a considerable advantage over those toolkits for
CRISPR/Cas9-based in vivo engineering that rely on the
temperature-sensitive pSG5 origin of replication. The authors
showed that using this approach, 94% of the colonies screened
contained the desired deletion and had lost the editing
plasmid. Lastly, Sun and collaborators ruled out any oﬀ-target
activity of Cas9 in few of their mutants, sequencing the eight
most likely sites that could have been targeted by their sgRNA,
as well as the PCR products generated when screening the
correct deletions at the target site. Unlike the other CRISPR/
Cas9-based streptomycete toolkits, the use of the method
developed by Sun and co-workers has not yet been reported in
the literature by other researchers.4 Strategies for in vitro CRISPR/Cas9-
based streptomycete genome
engineering
Soon aer the release of their CRISPR/Cas9-based toolkit for in
vivo genome engineering,13 Sun and collaborators also devel-
oped a strategy for in vitro CRISPR/Cas9-based DNA editing
(ICE), which was applied to refactor streptomycete BGCs.46 In
this toolkit, Cas9 is used as an in vitro programmable DNA
endonuclease in combination with an in vitro-transcribed
sgRNA with appropriate protospacer(s). The authors rst
conrmed the ability of Cas9 to generate DSBs in circular
molecules when incubated with diﬀerent sgRNAs, using as
a model the circular cloning plasmid pUC18. This revealed that,
due its 30–50 exonuclease activity, Cas9 produced in most cases
small-size (5–14 bp) deletions upstream of the target site.
However, the addition of T4 DNA polymerase to join the cohe-
sive ends generated by Cas9 reduced the extent of these dele-
tions. The design of the sgRNA and the choice of sgRNA
combinations appeared however to inuence considerably the
eﬃciency of seamless deletions. Sun and collaborators used
their in vitro CRISPR/Cas9 toolkit to generate gene deletions in
a 20 kb plasmid that harboured the BGC for the proteinThis journal is © The Royal Society of Chemistry 2019phosphatase inhibitor RK-682 (14) and a 40 kb plasmid that
contained the BGC for holomycin (15).47 In the rst case a 975
bp deletion was achieved in 32% of the clones screened,
whereas in the second case a 2817 bp deletion was accom-
plished only with a 16% eﬃciency. The authors then further
tested the potential of their toolkit to carry out gene insertions.
Combining a PCR-amplied gene for ampicillin resistance and
the Cas9-linearised vector that contained the BGC for 14, they
generated recombinant plasmids with ampicillin resistant. In
this case, it was not possible to determine the eﬃciency of the
insertion since the selection of clones was based on the
acquired ampicillin resistance trait. To date, apart from the
examples described by Sun and collaborators, no other appli-
cation of the ICE system has been reported in the literature.5 Bioinformatic tools for designing
CRISPR/Cas9 experiments
Diﬀerent CRISPR/Cas9-mediated genome engineering tools and
their eﬀective use in streptomycete genomes have been
described above. An important consideration to make is that
when planning such experiments, the user has to design the 20
bp protospacer based on two primary requirements: (i) that the
protospacer is directly upstream of a PAM sequence (NGG for S.
pyogenes Cas9); (ii) that the protospacer + PAM sequence is
unique in the genome. Streptomycete genomes are naturally
rich in potential PAM (NGG) sequences due to their high GC
content, so nding a protospacer within the target sequence is
generally not diﬃcult, depending obviously on the extension of
the target region. Finding a unique protospacer + PAM sequence
is, theoretically, also not challenging, given the relatively small
size of streptomycete genomes (normally between 7 and 10
Mbp) compared to higher organisms. However, it is known that
only the 13 bp sequence directly upstream of the PAM sequence
is strictly required to direct binding of Cas9 to the target site,
increasing considerably chances of oﬀ-target eﬀects.8 Moreover,
single and double mismatches in the core protospacer sequence
are known to be tolerated to varying degrees by Cas9, increasing
likelihood of oﬀ-target eﬀects even further.23,48 Designing
a protospacer that minimises chances of oﬀ-target eﬀects
requires therefore the use of bioinformatic tools. In order to
help designing the best protospacer for the desired target
sequence, several online and oﬄine bioinformatic tools have
been made available. One of these, which features a user-
friendly interface, is CRISPy-web,49 a platform developed by
Weber, Lee and collaborators. CRISPy-web rst requires
uploading the genome sequence of the specic strain of
interest, which can be provided in the form of a GenBank le or
an antiSMASH entry. The user then has to specify the target
region within the genomic entry, which prompts to an output
page with graphic interface that shows the location on the target
sequence of all hits found, followed by a table-like analysis of
the output. This includes, for each possible protospacer, the
number of oﬀ-target hits on the whole genomic sequence that
contain 0, 1, or 2 mismatches for the 13 bp core sequence
upstream of the PAM site. Based on this information, the userNat. Prod. Rep.
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View Article Onlinecan then choose whichever protospacer shows the lowest
chances of oﬀ-target eﬀects in the genome under study.6 Critical analysis of current toolkits
and prospects
The advent of CRISPR/Cas9 has revolutionised the way
researchers do genome engineering. Since the release of the
four available toolkits for in vivo CRISPR/Cas9-based engi-
neering for streptomycetes, several studies have been published
in which these have successfully been used for the purpose of
gene and whole BGC deletion, point mutations and insertions.
Among these toolkits, pCRISPomyces-2 (ref. 10) is the plasmid
that has seen the highest number of applications,17,24–31 showing
also the potential to be used in non-streptomycete Gram-
positive and even Gram-negative bacteria.29–31 It is interesting,
however, that pCRISPomyces-2 has not yet been reported to
work in S. coelicolor, which is considered the model species
among streptomycetes. At the time of writing, there is only one
published report of attempting its use in S. coelicolor, which was
described as unsuccessful,17 similarly to what reported for the
same plasmid in Streptomyces sp. KY 40-1.18 Out of the four
toolkits for in vivo CRISPR/Cas9-based streptomycete engi-
neering, two allow for inducible expression of cas9,11,12 which
can increase chances of obtaining ex-conjugants before Cas9 is
rendered active. Moreover, the one developed by Weber, Lee
and collaborators allows reversible gene knockdowns, through
CRISPRi,12 which can be useful for instance when aiming to
carry out biosynthetic studies on natural product BGCs. Similar
to pCRISPomyces-2, this toolkit has also been used in non-
streptomycete hosts, showing a wide potential of applica-
bility.41,43 It is worth mentioning that CRISPR/Cas9 is not the
only CRISPR/Cas system to have been developed for the use in
streptomycetes. Another class 2 CRISPR/Cas system called Cpf1
(CRISPR from Prevotella and Francisella 1) has recently been
developed into a streptomycete CRISPR toolbox.50 This system
can complement CRISPR/Cas9-based plasmids, giving the user
the option to use a T-rich PAM (TTTN for Cpf1, as opposed to
NGG for Cas9) and requiring only a crRNA (as opposed to crRNA
and tracrRNA for Cas9). It can also be used for multiplex gene
repression through CRISPRi, and it promises to work in strep-
tomycete strains in which Cas9 may not work, such as Strepto-
myces hygroscopicus SIPI-KF.50
One of the key advantages of using CRISPR/Cas9-based engi-
neering is the reduced timeframe compared to traditional
homologous recombination methods (Fig. 2).6,7 Several consec-
utive editing rounds can also be carried out in a reasonable time.
This is particularly true when using the pWHU2653 plasmid that
has a counter-selectable marker for plasmid loss aer the editing
event has taken place.13 Conversely, plasmid clearance for the
other three in vivo CRISPR/Cas9-based toolkits can be achieved
through few rounds of subculture at increased temperature (37–
39 C), somehow extending the experimental timeframe.
A general advantage of using CRISPR, in comparison to Red/
ET-based recombineering system,7 is that one does not normally
need to prepare a cosmid library but can instead directly work onNat. Prod. Rep.the strain of interest. It should be noted that this is also not
required when editing genomes through double crossover, which
is however less eﬃcient than CRISPR/Cas9-based engineering.
Cosmid clones, or other BGC-captured plasmids generated for
instance through TAR cloning, are still needed when using the in
vitro CRISPR/Cas9-based ICE toolkit,46 or when dealing with
genetically intractable strains.17 A minor issue that has been
encountered in a few instances when using CRISPR/Cas9-based
toolkits is the occurrence of strains with mixed phenotypes,10,11
which seems however to only account for a low percentage of the
strains screened. Another drawback that can be faced when
undertaking CRISPR/Cas9-based engineering, as opposed to
classical homologous recombination methods, is that Cas9 can
lead to oﬀ-target eﬀects due to its ability to toleratemismatches in
the protospacer sequence.23,48 The risk of such undesired events
can be reduced if using bioinformatic tools, such as CRISPy-
web,49 to choose the best protospacer. In fact, a given protospacer
may not produce the desired DSB, therefore oen the use of more
than one protospacer for each target may be advisable. In relation
to oﬀ-target eﬀects, given the aﬀordable cost, whole-genome
sequencing of the mutant strains generated may also be adop-
ted to rule out any unpredicted oﬀ-target editing, not only for
CRISPR/Cas9-mediated genome editing but also for other
genome editing approaches, such as Red/ET-based recombin-
eering system.
7 Conclusions
The CRISPR/Cas9-based toolkits developed for use in strepto-
mycetes have revolutionised the way researchers in this eld do
genome engineering with the aim to characterise natural
products and their biosynthesis. Since their release, successful
use of these toolkits has been reported for 13 diﬀerent Strep-
tomyces species, as well as on other non-streptomycete Gram-
positive and Gram-negative strains. Constraints related to
toxicity of Cas9 in the species of interest and the risk of oﬀ-
target eﬀects are notable limitations of CRISPR/Cas9-based
engineering. These can be addressed by cloning the BGC of
interest into a genetically tractable Cas9-veried species and
through an accurate protospacer design with the available
bioinformatic tools. In conclusion, due to its exibility and
ability to produce seamless and marker-less mutations in
a reduced timeframe, CRISPR/Cas9-based genome editing is
expected to overtake conventional methods of genetic engi-
neering in streptomycetes, not only for the purpose of natural
product discovery but also for studies of developmental biology
and synthetic biology applications such as engineering fusion
proteins in streptomycetes.
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